泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03347 泰格医药

休市中 05-08 16:08:03

38.180

-1.360

-3.44%

最高39.600	最低37.720	成交量127.26万
今开39.600	昨收39.540	日振幅4.75%
总市值328.73亿	流通市值47.01亿	总股本8.61亿
成交额4,886万	换手率1.03%	流通股本1.23亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03347","market":"HK","secType":"STK","nameCN":"泰格医药","latestPrice":38.18,"timestamp":1778227683008,"preClose":39.54,"halted":0,"volume":1272621,"delay":0,"changeRate":-0.034395548811330286,"floatShares":123124800,"shares":861000000,"eps":1.1978668837777326,"marketStatus":"休市中","change":-1.36,"latestTime":"05-08 16:08:03","open":39.6,"high":39.6,"low":37.72,"amount":48859880,"amplitude":0.047547,"askPrice":38.18,"askSize":100,"bidPrice":38.16,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":1.054687237313877,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778463000000},"marketStatusCode":7,"adr":0,"listingDate":1596729600000,"exchange":"SEHK","adjPreClose":39.54,"dividendRate":0.008499,"openAndCloseTimeList":[[1778203800000,1778212800000],[1778216400000,1778227200000]],"volumeRatio":0.817807,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"300347","market":"SZ","secType":"STK","nameCN":"泰格医药","latestPrice":51.16,"timestamp":1778223600000,"preClose":53.13,"halted":0,"volume":14341700,"delay":0,"premium":"-35.21"}},"requestUrl":"/m/hq/s/03347","defaultTab":"news","newsList":[{"id":"2633411477","title":"泰格医药（300347）披露将参加浙江辖区上市公司2026年投资者网上集体接待日暨2025年度业绩说明会，5月7日股价下跌1.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633411477","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633411477?lang=zh_cn&edition=full","pubTime":"2026-05-07 17:47","pubTimestamp":1778147233,"startTime":"0","endTime":"0","summary":"截至2026年5月7日收盘，泰格医药报收于53.13元，较前一交易日下跌1.57%，最新总市值为457.46亿元。该股当日开盘53.65元，最高54.18元，最低52.92元，成交额达6.59亿元，换手率为2.19%。近日，杭州泰格医药科技股份有限公司披露《关于参加浙江辖区上市公司2026年投资者网上集体接待日暨2025年度业绩说明会的公告》。公司高管将就2025年度业绩、公司治理、发展战略、经营状况等问题与投资者交流。公司现面向投资者公开征集问题，截止时间为2026年5月12日15:00。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700029889.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03347","LU1820825898.SGD","BK0077","BK0174","300347","BK1583","BK0028","BK1141","BK1576","BK0216","LU1146622755.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156986451","title":"泰格医药4月股份变动月报：股本结构维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1156986451","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156986451?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:41","pubTimestamp":1778056865,"startTime":"0","endTime":"0","summary":"杭州泰格医药科技股份有限公司于2026年5月6日披露了截至2026年4月30日的股份变动月报表。本月内公司注册股本及已发行股份整体未发生新增或减少，股本结构保持不变。根据公告，截至4月末，公司A股注册股本为737,901,250股，H股注册股本为123,124,800股，均与上月底保持一致；本月底法定/注册股本总额仍为人民币861,026,050元。截至2026年4月30日，公司尚持有5,883,780股A股库存股份。本次月报由公司董事叶小平署名并递交。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632279933","title":"高盛：下调泰格医药(03347)目标价至59.4港元 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2632279933","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632279933?lang=zh_cn&edition=full","pubTime":"2026-05-04 14:36","pubTimestamp":1777876599,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛发布研报称，将泰格医药(03347，300347.SZ)2026至2028年盈利预测下调12%、1%及4%，反映AI投资增加。泰格医药H股目标价由61.4港元下调至59.4港元，A股目标价由76.2元人民币下调至75.2元人民币，均维持“买入”评级。报告指，泰格医药首季收入同比增长15.2%至18亿元人民币，高于该行预期，受惠于国内创新药研发活动带动临床试验服务复苏。但期内经调整纯利1.2亿元人民币，低于该行预期的1.4亿元人民币，主因毛利率修复较预期慢，整体毛利率受旧合同执行、汇率因素及部分业务持续价格压力影响，降至26.6%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437801.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","03347","300347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632671668","title":"每周股票复盘：泰格医药（300347）Q1营收增15.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632671668","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632671668?lang=zh_cn&edition=full","pubTime":"2026-05-03 01:46","pubTimestamp":1777743975,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，泰格医药报收于55.2元，较上周的56.02元下跌1.46%。本周，泰格医药4月28日盘中最高价报59.5元。本周关注点业绩披露要点：泰格医药2026年一季报显示，一季度主营收入18.01亿元，同比上升15.17%。业绩披露要点泰格医药2026年一季报显示，一季度公司主营收入18.01亿元，同比上升15.17%；归母净利润4904.31万元，同比下降70.36%；扣非净利润1.2亿元，同比上升17.65%；负债率14.71%，投资收益3666.04万元，财务费用2215.99万元，毛利率26.64%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300000226.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300347","03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631578878","title":"泰格医药（300347）2026年一季报简析：增收不增利，公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2631578878","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631578878?lang=zh_cn&edition=full","pubTime":"2026-04-30 06:41","pubTimestamp":1777502509,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期泰格医药发布2026年一季报。截至本报告期末，公司营业总收入18.01亿元，同比上升15.17%，归母净利润4904.31万元，同比下降70.36%。本报告期泰格医药公司应收账款体量较大，当期应收账款占最新年报归母净利润比达153.2%。本次财报公布的各项数据指标表现一般。去年的净利率为11.78%，算上全部成本后，公司产品或服务的附加值一般。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000022594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300347","BK0028","03347","BK0174","BK1583","BK1141","BK0077","BK1576","LU1820825898.SGD","BK0216","LU1146622755.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134411210","title":"泰格医药更新末期股息安排，每10股派1.26元人民币待股东批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1134411210","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134411210?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:42","pubTimestamp":1777455768,"startTime":"0","endTime":"0","summary":"杭州泰格医药科技股份有限公司4月30日发布末期股息更新公告，公司拟就截至2025年12月31日止年度派发末期普通股息，每10股派发现金红利1.26元人民币（含税），该方案尚需经6月2日召开的股东大会批准。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"泰格医药更新末期股息安排，每10股派1.26元人民币待股东批准","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631595451","title":"泰格医药(03347)将于7月31日派发末期股息每10股1.26元","url":"https://stock-news.laohu8.com/highlight/detail?id=2631595451","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631595451?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:38","pubTimestamp":1777455527,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰格医药(03347)发布公告，该公司将于2026年7月31日派发截至2025年12月31日止年度的末期股息每10股1.26元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436266.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300347","BK0077","03347","LU1820825898.SGD","BK1141","BK4585","VIG","BK0174","BK1583","LU1146622755.USD","BK4588","BK1576","BK0216","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148610091","title":"泰格医药2025年度营收微增至68.33亿元 归母净利润大幅提升至8.88亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1148610091","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148610091?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:36","pubTimestamp":1777455387,"startTime":"0","endTime":"0","summary":"泰格医药于2025年度在临床研究服务与国际化布局方面均取得显著进展。公司全年实现营业收入68.33亿元人民币，同比上升3.5%。截至2025年12月31日，泰格医药资产总额为283.59亿元，较上年末微降1.1%；负债总额为41.02亿元，减少10.9%；本公司拥有人应占权益为209.60亿元，同比增长1.4%。总体而言，泰格医药2025年度在收入稳步增长的同时实现盈利水平大幅提升，并于海外市场及数字化升级等领域进一步拓展。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"泰格医药2025年度营收微增至68.33亿元 归母净利润大幅提升至8.88亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116662568","title":"泰格医药拟回购最多10%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1116662568","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116662568?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:31","pubTimestamp":1777455064,"startTime":"0","endTime":"0","summary":"泰格医药公告，公司董事会已提议授予股份购回一般授权，拟以合法资金回购不超过于授权当日已发行H股总数10%的股份。按照最新披露数据，泰格医药发行的H股为123,124,800股，若本次议案获通过，最大可回购股份数量约为12,312,480股。公司认为，回购股份有助提升每股价值并符合公司及股东的最佳利益。此次回购计划尚待2025年股东周年大会及2026年第一次H股类别股东大会审议批准。公司提示，届时将根据市场情况及公司资金与运营需求决定具体回购安排。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"泰格医药拟回购最多10%股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108478115","title":"异动解读 | 一季报净利润同比大降70%，泰格医药盘中大跌5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1108478115","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108478115?lang=zh_cn&edition=full","pubTime":"2026-04-29 09:36","pubTimestamp":1777426590,"startTime":"0","endTime":"0","summary":"泰格医药（03347）今日盘中股价大跌5%，引起了市场的广泛关注。消息面上，公司最新发布的2026年第一季度财报显示，尽管主营收入同比增长15.17%，但归母净利润仅为4904.31万元，同比大幅下降70.36%。这一关键财务数据的显著下滑，引发了投资者对公司短期盈利能力的担忧，可能是导致股价下跌的主要原因。泰格医药主营业务为临床试验技术服务和临床试验相关服务及实验室服务。此次财报显示，公司扣非净利润同比增长17.65%，负债率保持在14.71%的较低水平，但净利润的大幅收缩仍对市场情绪造成了直接冲击。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630376299","title":"泰格医药(03347)一季度归母净利润4904.3万元，同比下降70.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630376299","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630376299?lang=zh_cn&edition=full","pubTime":"2026-04-28 16:42","pubTimestamp":1777365747,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰格医药(03347)发布公告，2026年第一季度，营业收入18.01亿元，同比增长15.17%;归属于上市公司股东的净利润4904.3万元，同比下降70.36%;基本每股收益0.06元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435245.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300347","03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630382394","title":"泰格医药：截至2025年12月31日，公司股东人数为49,327人","url":"https://stock-news.laohu8.com/highlight/detail?id=2630382394","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630382394?lang=zh_cn&edition=full","pubTime":"2026-04-27 20:51","pubTimestamp":1777294281,"startTime":"0","endTime":"0","summary":"证券之星消息，泰格医药(300347)04月27日在投资者关系平台上答复投资者关心的问题。投资者提问：请问目前股东人数是多少？近期大股东或者公司是否有回购计划？泰格医药回复：投资者您好，根据公司2025年度报告中股东相关章节披露：截至2025年12月31日，公司股东人数为49,327人。公司后续如有回购计划会及时于巨潮资讯网披露公告，请您关注公司公告。谢谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700042924.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1146622755.USD","BK0216","BK0077","LU1820825898.SGD","03347","300347","BK0174","BK1141","BK1576","BK1583","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629076839","title":"Schroders PLC增持泰格医药(03347)29.98万股 每股作价约43.62港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629076839","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629076839?lang=zh_cn&edition=full","pubTime":"2026-04-23 19:46","pubTimestamp":1776944807,"startTime":"0","endTime":"0","summary":"香港联交所最新资料显示，4月20日，Schroders PLC增持泰格医药(03347)29.98万股，每股作价43.6247港元，总金额约为1307.87万港元。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260423/20260423194716_95321.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260423/20260423194716_95321.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432816.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0028","BK1576","EWH","BK1583","LU1820825898.SGD","LU1146622755.USD","BK0174","03347","300347","BK0216","BK1141","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629014767","title":"郭锐2026年一季度表现，招商丰盈积极配置混合A基金季度跌幅3.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629014767","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629014767?lang=zh_cn&edition=full","pubTime":"2026-04-22 17:59","pubTimestamp":1776851959,"startTime":"0","endTime":"0","summary":"证券之星消息，截止2026年一季度末，基金经理郭锐旗下共管理12只基金，本季度表现最佳的为招商丰盈积极配置混合A，季度净值跌3.21%。持有期间的估算收益率为358%，持有期间泰格医药在2019年到2021年的年报归属净利润增幅达241.5%。持有期间的估算收益率为-65.71%，持有期间东方雨虹在2022年到2024年的年报营业总收入降幅为10.12%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200041786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","BK1583","03347","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629014714","title":"张迎军2026年一季度表现，博道嘉兴一年持有期混合基金季度涨幅9.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629014714","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629014714?lang=zh_cn&edition=full","pubTime":"2026-04-22 17:56","pubTimestamp":1776851814,"startTime":"0","endTime":"0","summary":"证券之星消息，截止2026年一季度末，基金经理张迎军旗下共管理8只基金，本季度表现最佳的为博道嘉兴一年持有期混合，季度净值涨9.21%。张迎军在担任博道嘉泰回报混合基金经理的任职期间累计任职回报138.17%，平均年化收益率为14.66%。持有期间的估算收益率为93.07%，持有期间泰格医药在2020年到2021年的年报归属净利润增幅达64.26%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200041740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","BK1583","BK1141","03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629906966","title":"乔迁2026年一季度表现，兴全商业模式LOF基金季度涨幅3.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629906966","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629906966?lang=zh_cn&edition=full","pubTime":"2026-04-22 07:08","pubTimestamp":1776812892,"startTime":"0","endTime":"0","summary":"证券之星消息，截止2026年一季度末，基金经理乔迁旗下共管理2只基金，本季度表现最佳的为兴全商业模式LOF，季度净值涨3.42%。持有期间的估算收益率为615.76%，持有期间隆基股份在2018年到2020年的年报归属净利润增幅达234.34%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200013274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","BK1583","03347","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629309704","title":"周晶2026年一季度表现，银华回报定开混合基金季度涨幅10.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629309704","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629309704?lang=zh_cn&edition=full","pubTime":"2026-04-21 12:54","pubTimestamp":1776747257,"startTime":"0","endTime":"0","summary":"证券之星消息，截止2026年一季度末，基金经理周晶旗下共管理6只基金，本季度表现最佳的为银华回报定开混合，季度净值涨10.39%。周晶在担任银华-道琼斯88指数基金经理的任职期间累计任职回报66.29%，平均年化收益率为7.07%。期间重仓股调仓次数共有88次，其中盈利次数为53次，胜率为60.23%；翻倍级别收益有4次，翻倍率为4.55%。　　周晶管理的银华-道琼斯88指数基金在21年3季度买入泰格医药，在持有2个季度后在22年1季度卖出。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202604/21/20260421798948.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202604/21/20260421798948.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260421/32159593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["DIA","GRNY","VYMI","FDN","DGRW","DGRO","YMAX","DOG","DDM","DXD","BK1583","SCHD","BK1576","VUG","BK1141","SCHG","MGK","XLI","VYM","03347",".DJI","TOPT","FDVV","DVY","UDOW","SDOW","SDY","DJX","DJIA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629701282","title":"神爱前2026年一季度表现，平安产业趋势混合A基金季度涨幅6.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629701282","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629701282?lang=zh_cn&edition=full","pubTime":"2026-04-21 12:26","pubTimestamp":1776745610,"startTime":"0","endTime":"0","summary":"证券之星消息，截止2026年一季度末，基金经理神爱前旗下共管理5只基金，本季度表现最佳的为平安产业趋势混合A，季度净值涨6.1%。持有期间的估算收益率为91.99%，持有期间中际旭创在2023年到2024年的年报归属净利润增幅达137.93%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100025754.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","BK1141","03347","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628221164","title":"港股异动 | CXO 概念股跌幅居前 海外投融资大环境进入波动阶段 AI制药或导致研发及临床端分化","url":"https://stock-news.laohu8.com/highlight/detail?id=2628221164","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628221164?lang=zh_cn&edition=full","pubTime":"2026-04-17 11:31","pubTimestamp":1776396664,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，CXO概念股跌幅居前，截至发稿，昭衍新药跌5.82%，报21.7港元；康龙化成跌3.65%，报21.1港元；泰格医药跌3.02%，报42.46港元。中信建投发布研报称，海外投融资大环境进入季度间波动，不同阶段、不同疾病领域的CXO服务需求进一步分化，国内投融资活动景气度持续上行，弹性更强，持续看好CXO板块成长空间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429805.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK4585","VXUS","AGIX","03759","CHAT","01477","BK1574","BK1583","CXO","AIPO","BK4588","03347","ARTY","06127","BK1576","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628129223","title":"泰格医药与英硅智能签署战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2628129223","media":"第一财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628129223?lang=zh_cn&edition=full","pubTime":"2026-04-17 09:06","pubTimestamp":1776387982,"startTime":"0","endTime":"0","summary":"2026年4月16日，杭州泰格医药科技股份有限公司与生成式人工智能驱动的临床阶段生物医药科技公司英硅智能签署战略合作协议。双方将围绕创新药产品的临床研究开展长期战略合作，通过AI来驱动药物研发提速增效，助力创新药更快落地、惠及全球患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604173708366528.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604173708366528.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["300347","BK0028","03347","BK0077","BK0216","LU1146622755.USD","BK1583","BK0174","BK1141","BK1576","LU1820825898.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tigermed.net","stockEarnings":[{"period":"1week","weight":-0.0493},{"period":"1month","weight":-0.1042},{"period":"3month","weight":-0.293},{"period":"6month","weight":-0.1029},{"period":"1year","weight":0.4229},{"period":"ytd","weight":-0.1025}],"compareEarnings":[{"period":"1week","weight":0.0239},{"period":"1month","weight":0.0193},{"period":"3month","weight":-0.0063},{"period":"6month","weight":0.0058},{"period":"1year","weight":0.1588},{"period":"ytd","weight":0.0298}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"杭州泰格医药科技股份有限公司是一家从事为新药研发提供临床试验服务的中国控股公司。该公司经营两个分部。临床试验技术服务分部向生物制药和医疗器械公司提供临床试验运作服务和医学翻译等服务，帮助其进行创新药物、仿制药和医疗器械的临床试验。临床试验相关服务及实验室服务分部从事提供分析服务，比如数据管理和统计分析；后勤和执行支持服务，比如临床试验现场管理；行政协助，比如患者招募；以及咨询服务等。该分部同时通过其子公司为临床前和临床开发阶段提供实验室服务。该公司在国内市场和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.03226},{"month":2,"riseRate":0.5,"avgChangeRate":0.003406},{"month":3,"riseRate":0.5,"avgChangeRate":-0.03269},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.051086},{"month":5,"riseRate":0.333333,"avgChangeRate":0.017775},{"month":6,"riseRate":0.6,"avgChangeRate":0.024718},{"month":7,"riseRate":0.6,"avgChangeRate":0.079529},{"month":8,"riseRate":0,"avgChangeRate":-0.091864},{"month":9,"riseRate":0.333333,"avgChangeRate":0.032065},{"month":10,"riseRate":0.5,"avgChangeRate":-0.02594},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.001375},{"month":12,"riseRate":0.5,"avgChangeRate":0.041249}],"exchange":"SEHK","name":"泰格医药","nameEN":"TIGERMED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰格医药(03347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰格医药,03347,泰格医药股票,泰格医药股票老虎,泰格医药股票老虎国际,泰格医药行情,泰格医药股票行情,泰格医药股价,泰格医药股市,泰格医药股票价格,泰格医药股票交易,泰格医药股票购买,泰格医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰格医药(03347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}